Normothermic Machine Perfusion after Simvastatin Donor Treatment for prevention of ischemia-reperfusion injury in Liver Transplantation

Abstract
Our proposal for close monitoring of IRI and immune-inflammatory state can apply the concept of precision medicine to MP, and be translated in clinical setting and future targets for widespread use of liver grafts from ECD Fundamental hypothesis: identification of feasibility and advantages of avoiding the second recooling to 0-4 C after NMP with or without Simvastatin treatment of whole liver from ECD. Despite NMP technology has improved the pool of liver grafts in the clinical setting, many fields of its management are still obscure and the effect on blood cells and IRI mediators has still to be highlighted. IRI leads to liver congestion, progressive thrombosis, and necrosis of organs, resulting in the failure of LT with evidence of primary-non-function (PNF) defined as the absence of or minimal function of a liver graft after transplantation requiring retransplantation or leading to patient death within 7 days after the procedure
Keywords
LIVER TRANSPLANTATION
MACHINE PERFUSION
ISHEMIA-REPERFUSION INJURY
EXPANDED CRITERIA DONOR
SIMVASTATIN
ERC sector(s)
LS Life Sciences
Name supervisor
Salvatore Gruttadauria
E-mail
sgruttadauria@unict.it
Name of Department/Faculty/School
Department of Surgery and Medical and Surgical Specialties, University of Catania, 95124, Catania, Italy
Name of the host University
University of Catania (UNICT)
EUNICE partner e-mail of destination Research
eunice@unict.it
Country
Italy
Thesis level
PhD
Minimal language knowledge requisite
English B2
Thesis mode
On-site
Start date
Length of the research internship
12 months
Financial support available (other than E+)
No